SK13952002A3 - Farmaceutická kompozícia na liečenie akútnej, chronickej a/alebo neuropatickej bolesti a migrén - Google Patents

Farmaceutická kompozícia na liečenie akútnej, chronickej a/alebo neuropatickej bolesti a migrén Download PDF

Info

Publication number: SK13952002A3
Authority: SK; Slovakia
Prior art keywords: triene; methyl; hexahydro; methano; pyrido
Prior art date: 2000-04-07

Application number

SK1395-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Jotham Wadsworth Coe

Edmund Patrick Harrigan

Brian Thomas O'neill

Steven Bradley Sands

Eric Jacob Watsky

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-07

Filing date

2001-03-16

Publication date

2003-12-02

2001-03-16 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2003-12-02 Publication of SK13952002A3 publication Critical patent/SK13952002A3/sk

Links

208000002193 Pain Diseases 0.000 title claims abstract description 100
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 35
208000019695 Migraine disease Diseases 0.000 title claims abstract description 32
230000001154 acute effect Effects 0.000 title claims abstract description 26
208000004296 neuralgia Diseases 0.000 title claims abstract description 23
208000021722 neuropathic pain Diseases 0.000 title claims abstract description 23
208000000094 Chronic Pain Diseases 0.000 title claims abstract description 22
238000000034 method Methods 0.000 claims abstract description 93
150000001875 compounds Chemical class 0.000 claims abstract description 61
239000000730 antalgic agent Substances 0.000 claims abstract description 51
-1 anti-arrythmics Substances 0.000 claims abstract description 38
206010027599 migraine Diseases 0.000 claims abstract description 31
208000005298 acute pain Diseases 0.000 claims abstract description 24
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 22
239000004031 partial agonist Substances 0.000 claims abstract description 22
230000001684 chronic effect Effects 0.000 claims abstract description 20
241000124008 Mammalia Species 0.000 claims abstract description 15
229940123445 Tricyclic antidepressant Drugs 0.000 claims abstract description 14
239000001961 anticonvulsive agent Substances 0.000 claims abstract description 14
239000003029 tricyclic antidepressant agent Substances 0.000 claims abstract description 14
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 11
239000005557 antagonist Substances 0.000 claims abstract description 11
229960001948 caffeine Drugs 0.000 claims abstract description 11
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 11
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims abstract description 11
229940125681 anticonvulsant agent Drugs 0.000 claims abstract description 10
229940049706 benzodiazepine Drugs 0.000 claims abstract description 10
239000003937 drug carrier Substances 0.000 claims abstract description 10
239000003158 myorelaxant agent Substances 0.000 claims abstract description 10
239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims abstract description 9
239000003890 substance P antagonist Substances 0.000 claims abstract description 9
239000003193 general anesthetic agent Substances 0.000 claims abstract description 8
239000000014 opioid analgesic Substances 0.000 claims abstract description 8
239000000018 receptor agonist Substances 0.000 claims abstract description 8
229940044601 receptor agonist Drugs 0.000 claims abstract description 8
108010062740 TRPV Cation Channels Proteins 0.000 claims abstract description 7
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims abstract description 7
229940005483 opioid analgesics Drugs 0.000 claims abstract description 7
150000003431 steroids Chemical class 0.000 claims abstract description 7
108030001720 Bontoxilysin Proteins 0.000 claims abstract description 6
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims abstract description 6
101000942305 Zea mays Cytokinin dehydrogenase 1 Proteins 0.000 claims abstract description 6
239000000739 antihistaminic agent Substances 0.000 claims abstract description 6
150000001557 benzodiazepines Chemical class 0.000 claims abstract description 6
229940053031 botulinum toxin Drugs 0.000 claims abstract description 6
229940111134 coxibs Drugs 0.000 claims abstract description 6
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims abstract description 6
229940125706 skeletal muscle relaxant agent Drugs 0.000 claims abstract description 6
230000001773 anti-convulsant effect Effects 0.000 claims abstract description 5
229940125715 antihistaminic agent Drugs 0.000 claims abstract description 5
229940030600 antihypertensive agent Drugs 0.000 claims abstract description 5
239000002220 antihypertensive agent Substances 0.000 claims abstract description 5
230000003288 anthiarrhythmic effect Effects 0.000 claims abstract description 4
239000000203 mixture Substances 0.000 claims description 82
150000003839 salts Chemical class 0.000 claims description 60
230000036407 pain Effects 0.000 claims description 54
230000003287 optical effect Effects 0.000 claims description 34
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims description 22
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims description 22
230000006378 damage Effects 0.000 claims description 16
210000005036 nerve Anatomy 0.000 claims description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical group [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 10
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 10
208000014674 injury Diseases 0.000 claims description 9
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 8
206010019233 Headaches Diseases 0.000 claims description 8
239000013543 active substance Substances 0.000 claims description 8
231100000869 headache Toxicity 0.000 claims description 8
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 8
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 8
208000033808 peripheral neuropathy Diseases 0.000 claims description 8
208000004371 toothache Diseases 0.000 claims description 8
230000008733 trauma Effects 0.000 claims description 8
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical group OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 7
210000001519 tissue Anatomy 0.000 claims description 7
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 6
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 6
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 6
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 6
102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 claims description 6
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 6
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims description 6
HYDLTSOVXCUHPA-UHFFFAOYSA-N ctk0j4563 Chemical compound C1NCC2CC3=C(F)C(F)=CC=C3C1C2 HYDLTSOVXCUHPA-UHFFFAOYSA-N 0.000 claims description 6
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical group N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 6
208000035475 disorder Diseases 0.000 claims description 6
229960004502 levodopa Drugs 0.000 claims description 6
BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 claims description 6
229960002811 ziconotide Drugs 0.000 claims description 6
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 5
ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims description 5
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 5
DWDCLEHDNICBMI-UHFFFAOYSA-N 3-bromocytisine Chemical compound C1C2CNCC1CN1C2=CC=C(Br)C1=O DWDCLEHDNICBMI-UHFFFAOYSA-N 0.000 claims description 5
UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 claims description 5
HYHCJHBDDKMCTD-UHFFFAOYSA-N C1C2CNCC1CN1C2=CC=C(F)C1=O Chemical compound C1C2CNCC1CN1C2=CC=C(F)C1=O HYHCJHBDDKMCTD-UHFFFAOYSA-N 0.000 claims description 5
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 5
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 5
VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims description 5
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 5
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 5
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 5
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 5
RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 5
229960004538 alprazolam Drugs 0.000 claims description 5
229960003150 bupivacaine Drugs 0.000 claims description 5
229960000590 celecoxib Drugs 0.000 claims description 5
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 5
210000003169 central nervous system Anatomy 0.000 claims description 5
229960004782 chlordiazepoxide Drugs 0.000 claims description 5
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims description 5
229960002023 chloroprocaine Drugs 0.000 claims description 5
229960002896 clonidine Drugs 0.000 claims description 5
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 5
229960003914 desipramine Drugs 0.000 claims description 5
229960001985 dextromethorphan Drugs 0.000 claims description 5
229960003529 diazepam Drugs 0.000 claims description 5
229960001259 diclofenac Drugs 0.000 claims description 5
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 5
229960003976 etidocaine Drugs 0.000 claims description 5
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 claims description 5
229960003132 halothane Drugs 0.000 claims description 5
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 5
229960001680 ibuprofen Drugs 0.000 claims description 5
229960003998 ifenprodil Drugs 0.000 claims description 5
229960000905 indomethacin Drugs 0.000 claims description 5
230000002401 inhibitory effect Effects 0.000 claims description 5
229960004194 lidocaine Drugs 0.000 claims description 5
229960004391 lorazepam Drugs 0.000 claims description 5
229960002009 naproxen Drugs 0.000 claims description 5
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 5
229960005254 naratriptan Drugs 0.000 claims description 5
239000001272 nitrous oxide Substances 0.000 claims description 5
230000002093 peripheral effect Effects 0.000 claims description 5
229960000762 perphenazine Drugs 0.000 claims description 5
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 5
229960004618 prednisone Drugs 0.000 claims description 5
229960000425 rizatriptan Drugs 0.000 claims description 5
TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 claims description 5
229960000371 rofecoxib Drugs 0.000 claims description 5
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical group C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 5
229960001549 ropivacaine Drugs 0.000 claims description 5
229960002073 sertraline Drugs 0.000 claims description 5
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 5
229960003708 sumatriptan Drugs 0.000 claims description 5
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 5
IGRXMNYYQGKFCK-UHFFFAOYSA-N trideca-2,4,6-triene Chemical compound CCCCCCC=CC=CC=CC IGRXMNYYQGKFCK-UHFFFAOYSA-N 0.000 claims description 5
229960001360 zolmitriptan Drugs 0.000 claims description 5
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 4
IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims description 4
GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 claims description 4
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 4
125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 4
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 4
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 4
VHMDFCVLQUZHMQ-UHFFFAOYSA-N 9-vinyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one Chemical compound C1C2CNCC1CN1C2=CC=C(C=C)C1=O VHMDFCVLQUZHMQ-UHFFFAOYSA-N 0.000 claims description 4
208000004998 Abdominal Pain Diseases 0.000 claims description 4
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
208000008035 Back Pain Diseases 0.000 claims description 4
JTVKNZNCCOMFMG-UHFFFAOYSA-N C1C2CNCC1CC1=C2C=CC=C1C(F)(F)F Chemical compound C1C2CNCC1CC1=C2C=CC=C1C(F)(F)F JTVKNZNCCOMFMG-UHFFFAOYSA-N 0.000 claims description 4
MYEABNSFVNHLCV-UHFFFAOYSA-N C1C2CNCC1CN1C2=CC=C(C)C1=O Chemical compound C1C2CNCC1CN1C2=CC=C(C)C1=O MYEABNSFVNHLCV-UHFFFAOYSA-N 0.000 claims description 4
101150071146 COX2 gene Proteins 0.000 claims description 4
101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 claims description 4
229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
208000006561 Cluster Headache Diseases 0.000 claims description 4
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 4
206010013935 Dysmenorrhoea Diseases 0.000 claims description 4
206010015958 Eye pain Diseases 0.000 claims description 4
206010016059 Facial pain Diseases 0.000 claims description 4
208000007914 Labor Pain Diseases 0.000 claims description 4
208000035945 Labour pain Diseases 0.000 claims description 4
208000008930 Low Back Pain Diseases 0.000 claims description 4
206010028391 Musculoskeletal Pain Diseases 0.000 claims description 4
208000000112 Myalgia Diseases 0.000 claims description 4
208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 4
101150000187 PTGS2 gene Proteins 0.000 claims description 4
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 4
208000004550 Postoperative Pain Diseases 0.000 claims description 4
206010049002 Scar pain Diseases 0.000 claims description 4
208000008765 Sciatica Diseases 0.000 claims description 4
206010040744 Sinus headache Diseases 0.000 claims description 4
206010043269 Tension headache Diseases 0.000 claims description 4
208000008548 Tension-Type Headache Diseases 0.000 claims description 4
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 4
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 4
229960000836 amitriptyline Drugs 0.000 claims description 4
238000002266 amputation Methods 0.000 claims description 4
239000003416 antiarrhythmic agent Substances 0.000 claims description 4
229960003965 antiepileptics Drugs 0.000 claims description 4
210000000133 brain stem Anatomy 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
229960000623 carbamazepine Drugs 0.000 claims description 4
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 4
OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 claims description 4
229960004587 carisoprodol Drugs 0.000 claims description 4
GQVTUDRXPMPVRX-UHFFFAOYSA-N chembl62858 Chemical compound C1C2CNCC1CN1C2=CC=C(I)C1=O GQVTUDRXPMPVRX-UHFFFAOYSA-N 0.000 claims description 4
208000018912 cluster headache syndrome Diseases 0.000 claims description 4
229960004126 codeine Drugs 0.000 claims description 4
JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 claims description 4
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical group C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims description 4
229960004193 dextropropoxyphene Drugs 0.000 claims description 4
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 4
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 4
229950005455 eliprodil Drugs 0.000 claims description 4
229940099283 flexeril Drugs 0.000 claims description 4
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 4
229960000240 hydrocodone Drugs 0.000 claims description 4
229960001410 hydromorphone Drugs 0.000 claims description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
229960005181 morphine Drugs 0.000 claims description 4
208000013465 muscle pain Diseases 0.000 claims description 4
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims description 4
229960001730 nitrous oxide Drugs 0.000 claims description 4
QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 claims description 4
201000008482 osteoarthritis Diseases 0.000 claims description 4
229960002296 paroxetine Drugs 0.000 claims description 4
YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 claims description 4
229960000482 pethidine Drugs 0.000 claims description 4
BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims description 4
229960002601 protriptyline Drugs 0.000 claims description 4
206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
210000002027 skeletal muscle Anatomy 0.000 claims description 4
210000004872 soft tissue Anatomy 0.000 claims description 4
210000000278 spinal cord Anatomy 0.000 claims description 4
229960004394 topiramate Drugs 0.000 claims description 4
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 4
229960003741 tranylcypromine Drugs 0.000 claims description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
208000009935 visceral pain Diseases 0.000 claims description 4
206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical group OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 3
102000004129 N-Type Calcium Channels Human genes 0.000 claims description 3
108090000699 N-Type Calcium Channels Proteins 0.000 claims description 3
229960000794 baclofen Drugs 0.000 claims description 3
210000003461 brachial plexus Anatomy 0.000 claims description 3
229960002870 gabapentin Drugs 0.000 claims description 3
210000004086 maxillary sinus Anatomy 0.000 claims description 3
PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims description 3
229960001810 meprednisone Drugs 0.000 claims description 3
208000030062 persistent idiopathic facial pain Diseases 0.000 claims description 3
229960002702 piroxicam Drugs 0.000 claims description 3
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 3
238000007790 scraping Methods 0.000 claims description 3
206010044652 trigeminal neuralgia Diseases 0.000 claims description 3
MGQATKFFMYTJKY-UHFFFAOYSA-N C=1C=C2C(C3)CNCC3CN2C(=O)C=1C1=CC=CC=C1 Chemical compound C=1C=C2C(C3)CNCC3CN2C(=O)C=1C1=CC=CC=C1 MGQATKFFMYTJKY-UHFFFAOYSA-N 0.000 claims description 2
210000000576 arachnoid Anatomy 0.000 claims description 2
229940080861 demerol Drugs 0.000 claims description 2
QMQBBUPJKANITL-MYXGOWFTSA-N dextropropoxyphene hydrochloride Chemical compound [H+].[Cl-].C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 QMQBBUPJKANITL-MYXGOWFTSA-N 0.000 claims description 2
229940089568 lortab Drugs 0.000 claims description 2
DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims 4
JASMWYNKLTULAN-UHFFFAOYSA-N octan-3-amine Chemical compound CCCCCC(N)CC JASMWYNKLTULAN-UHFFFAOYSA-N 0.000 claims 3
FCDRFVCGMLUYPG-ROUUACIJSA-N (2S,3S)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CO[C@@H]2[C@@H](NCCC2)C=2C=CC=CC=2)=C1 FCDRFVCGMLUYPG-ROUUACIJSA-N 0.000 claims 2
UGIPKCIBIXXIEF-HNAYVOBHSA-N (2s,3s)-3-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-1-amine Chemical compound COC1=CC=C(OC(F)(F)F)C=C1C[C@H]1[C@@H](C=2C=CC=CC=2)N(N)CCC1 UGIPKCIBIXXIEF-HNAYVOBHSA-N 0.000 claims 2
HNJWADLEEJCOFQ-UHFFFAOYSA-N 2-[3-[[(2-benzhydryl-1-azabicyclo[2.2.2]octan-3-yl)amino]methyl]-4-methoxyphenyl]-2-methylpropan-1-ol Chemical compound COC1=CC=C(C(C)(C)CO)C=C1CNC1C(C(C=2C=CC=CC=2)C=2C=CC=CC=2)N2CCC1CC2 HNJWADLEEJCOFQ-UHFFFAOYSA-N 0.000 claims 2
OYKIXMQKLMUJEK-UHFFFAOYSA-N 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenylmorpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(COC2C(N(CC=3NC(=O)NN=3)CCO2)C=2C=CC=CC=2)=C1 OYKIXMQKLMUJEK-UHFFFAOYSA-N 0.000 claims 2
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical group CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims 2
XAHYMEDFEVWJKE-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-phenyl-1-propylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound CCCN1CCCC(NCC=2C(=CC=3CCC(=O)N(C)C=3C=2)OC)C1C1=CC=CC=C1 XAHYMEDFEVWJKE-UHFFFAOYSA-N 0.000 claims 2
CGVFPUYVFBJOCY-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 CGVFPUYVFBJOCY-UHFFFAOYSA-N 0.000 claims 2
DSKKJBPDHBFEOV-UHFFFAOYSA-N 6-methoxy-5-[(2-phenylpiperidin-1-yl)methyl]-3-(trifluoromethyl)-1,2-benzoxazole Chemical compound COC1=CC2=C(C(=NO2)C(F)(F)F)C=C1CN1C(CCCC1)C1=CC=CC=C1 DSKKJBPDHBFEOV-UHFFFAOYSA-N 0.000 claims 2
CKULNPVHUCWUPO-UHFFFAOYSA-N 7-methoxy-1-methyl-6-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2N(C)C(=O)CCC=2C=C1CNC1CCCNC1C1=CC=CC=C1 CKULNPVHUCWUPO-UHFFFAOYSA-N 0.000 claims 2
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
XVFCRSOWSDNUPD-UHFFFAOYSA-N n-[[2-methoxy-5-(1,1,1-trifluoro-2-methylbut-3-yn-2-yl)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(C(C)(C#C)C(F)(F)F)C=C1CNC1C(C=2C=CC=CC=2)NCCC1 XVFCRSOWSDNUPD-UHFFFAOYSA-N 0.000 claims 2
XOHNGGNSGAFTFL-UHFFFAOYSA-N n-[[5-(1,1,1,3,3,3-hexafluoropropan-2-yl)-2-methoxyphenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(C(C(F)(F)F)C(F)(F)F)C=C1CNC1C(C=2C=CC=CC=2)NCCC1 XOHNGGNSGAFTFL-UHFFFAOYSA-N 0.000 claims 2
ODEBBNRINYMIRX-UHFFFAOYSA-N n-[[6-methoxy-1-methyl-1-(trifluoromethyl)-3,4-dihydroisochromen-7-yl]methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=2CCOC(C)(C(F)(F)F)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 ODEBBNRINYMIRX-UHFFFAOYSA-N 0.000 claims 2
AMKVXSZCKVJAGH-UHFFFAOYSA-N naratriptan Chemical compound C12=CC(CCS(=O)(=O)NC)=CC=C2NC=C1C1CCN(C)CC1 AMKVXSZCKVJAGH-UHFFFAOYSA-N 0.000 claims 2
239000004084 narcotic analgesic agent Substances 0.000 claims 2
ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 claims 2
CLEMOHZZIAAIFC-CONSDPRKSA-N (2s,3s)-2-benzhydryl-n-(2-methoxy-5-propylphenyl)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound CCCC1=CC=C(OC)C(N[C@@H]2[C@](N3CCC2CC3)(C)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 CLEMOHZZIAAIFC-CONSDPRKSA-N 0.000 claims 1
QSBHMJMADHILTB-KYJUHHDHSA-N (2s,3s)-2-benzhydryl-n-(5-ethyl-2-methoxyphenyl)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound CCC1=CC=C(OC)C(N[C@@H]2[C@](N3CCC2CC3)(C)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 QSBHMJMADHILTB-KYJUHHDHSA-N 0.000 claims 1
UQMBAZSMZOUVTF-UHFFFAOYSA-N 2-benzhydryl-2-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound NC1C(CC2)CCN2C1(C)C(C=1C=CC=CC=1)C1=CC=CC=C1 UQMBAZSMZOUVTF-UHFFFAOYSA-N 0.000 claims 1
201000006390 Brachial Plexus Neuritis Diseases 0.000 claims 1
ZUXXFRXUPFGGPW-UHFFFAOYSA-N C12=CC=C(Br)C(=O)N2CC2CN(C)CC1C2 Chemical compound C12=CC=C(Br)C(=O)N2CC2CN(C)CC1C2 ZUXXFRXUPFGGPW-UHFFFAOYSA-N 0.000 claims 1
VIPDMOOFKWHQRH-UHFFFAOYSA-N C1N2C(=O)C(Br)=CC=C2C(C2)CC1CN2CC1=CC=CC=C1 Chemical compound C1N2C(=O)C(Br)=CC=C2C(C2)CC1CN2CC1=CC=CC=C1 VIPDMOOFKWHQRH-UHFFFAOYSA-N 0.000 claims 1
NDJKXXJCMXVBJW-UHFFFAOYSA-N Heptadecane Natural products CCCCCCCCCCCCCCCCC NDJKXXJCMXVBJW-UHFFFAOYSA-N 0.000 claims 1
101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 claims 1
101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 claims 1
208000028389 Nerve injury Diseases 0.000 claims 1
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 1
230000001430 anti-depressive effect Effects 0.000 claims 1
239000000935 antidepressant agent Substances 0.000 claims 1
229940005513 antidepressants Drugs 0.000 claims 1
230000001815 facial effect Effects 0.000 claims 1
239000003612 morphinomimetic agent Substances 0.000 claims 1
WUTRELIDULYHSO-UHFFFAOYSA-N n-[[2-methoxy-5-(1,1,1-trifluoro-2-methylpropan-2-yl)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(C(C)(C)C(F)(F)F)C=C1CNC1C(C=2C=CC=CC=2)NCCC1 WUTRELIDULYHSO-UHFFFAOYSA-N 0.000 claims 1
230000008764 nerve damage Effects 0.000 claims 1
201000001119 neuropathy Diseases 0.000 claims 1
230000007823 neuropathy Effects 0.000 claims 1
210000003901 trigeminal nerve Anatomy 0.000 claims 1
229960002715 nicotine Drugs 0.000 abstract description 8
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract description 6
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract description 5
239000003814 drug Substances 0.000 abstract description 3
230000003276 anti-hypertensive effect Effects 0.000 abstract description 2
229940124597 therapeutic agent Drugs 0.000 abstract description 2
102000011040 TRPV Cation Channels Human genes 0.000 abstract 1
238000012360 testing method Methods 0.000 description 20
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
241001465754 Metazoa Species 0.000 description 12
238000003556 assay Methods 0.000 description 12
230000000694 effects Effects 0.000 description 12
241000700159 Rattus Species 0.000 description 11
239000007864 aqueous solution Substances 0.000 description 8
239000012528 membrane Substances 0.000 description 8
241000282412 Homo Species 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
230000027455 binding Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
206010070834 Sensitisation Diseases 0.000 description 4
229960001138 acetylsalicylic acid Drugs 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
239000000872 buffer Substances 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
230000008313 sensitization Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 3
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
230000000202 analgesic effect Effects 0.000 description 3
239000012736 aqueous medium Substances 0.000 description 3
239000012131 assay buffer Substances 0.000 description 3
ODQWQRRAPPTVAG-BOPFTXTBSA-N cis-doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)\C2=CC=CC=C21 ODQWQRRAPPTVAG-BOPFTXTBSA-N 0.000 description 3
ANJTVLIZGCUXLD-DTWKUNHWSA-N cytisine Chemical compound C1NC[C@H]2CN3C(=O)C=CC=C3[C@@H]1C2 ANJTVLIZGCUXLD-DTWKUNHWSA-N 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229960005426 doxepin Drugs 0.000 description 3
238000001914 filtration Methods 0.000 description 3
229960002464 fluoxetine Drugs 0.000 description 3
210000002683 foot Anatomy 0.000 description 3
229960000930 hydroxyzine Drugs 0.000 description 3
ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 3
230000003040 nociceptive effect Effects 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
230000008447 perception Effects 0.000 description 3
229960001233 pregabalin Drugs 0.000 description 3
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 3
230000008569 process Effects 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
HRVMVUUOSIHXEI-UHFFFAOYSA-N C1C2CNCC1CN1C2=CC=C(CC)C1=O Chemical compound C1C2CNCC1CN1C2=CC=C(CC)C1=O HRVMVUUOSIHXEI-UHFFFAOYSA-N 0.000 description 2
108090000312 Calcium Channels Proteins 0.000 description 2
102000003922 Calcium Channels Human genes 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
206010028347 Muscle twitching Diseases 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
229920005372 Plexiglas® Polymers 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
230000002411 adverse Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
229960000520 diphenhydramine Drugs 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000008693 nausea Effects 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
239000000181 nicotinic agonist Substances 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
230000037324 pain perception Effects 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
239000004926 polymethyl methacrylate Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000001525 receptor binding assay Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000011514 reflex Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
229960000604 valproic acid Drugs 0.000 description 2
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
229940124638 COX inhibitor Drugs 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010053155 Epigastric discomfort Diseases 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010038678 Respiratory depression Diseases 0.000 description 1
241000208442 Sarracenia Species 0.000 description 1
241000208437 Sarraceniaceae Species 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
201000002661 Spondylitis Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
230000003502 anti-nociceptive effect Effects 0.000 description 1
229940125684 antimigraine agent Drugs 0.000 description 1
239000002282 antimigraine agent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
206010003074 arachnoiditis Diseases 0.000 description 1
229940072698 ativan Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000006399 behavior Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
210000001217 buttock Anatomy 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
230000009956 central mechanism Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
NBGMTBMAENFSAW-UHFFFAOYSA-N chembl64496 Chemical compound C1C2CNCC1CN1C2=CC=C(Cl)C1=O NBGMTBMAENFSAW-UHFFFAOYSA-N 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000006949 cholinergic function Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940119321 dantrium Drugs 0.000 description 1
LTWQNYPDAUSXBC-CDJGKPBYSA-L dantrolene sodium hemiheptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1.C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1 LTWQNYPDAUSXBC-CDJGKPBYSA-L 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
229940099212 dilaudid Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000000574 ganglionic effect Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003292 glue Substances 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
229940072228 neurontin Drugs 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
230000008058 pain sensation Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000009955 peripheral mechanism Effects 0.000 description 1
208000027232 peripheral nervous system disease Diseases 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000012552 review Methods 0.000 description 1
238000009666 routine test Methods 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
230000037152 sensory function Effects 0.000 description 1
230000020341 sensory perception of pain Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
230000000697 serotonin reuptake Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000010998 test method Methods 0.000 description 1
229960004380 tramadol Drugs 0.000 description 1
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229960001124 trientine Drugs 0.000 description 1
229960002431 trimipramine Drugs 0.000 description 1
ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
229940072690 valium Drugs 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229940074158 xanax Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1395-2002A 2000-04-07 2001-03-16 Farmaceutická kompozícia na liečenie akútnej, chronickej a/alebo neuropatickej bolesti a migrén SK13952002A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19573800P	2000-04-07	2000-04-07
PCT/IB2001/000391 WO2001076576A2 (fr)	2000-04-07	2001-03-16	Composition pharmaceutique servant a traiter une douleur chronique aigue et/ou une douleur neurophatique ou des migraines

Publications (1)

Publication Number	Publication Date
SK13952002A3 true SK13952002A3 (sk)	2003-12-02

Family

ID=22722582

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1395-2002A SK13952002A3 (sk)	2000-04-07	2001-03-16	Farmaceutická kompozícia na liečenie akútnej, chronickej a/alebo neuropatickej bolesti a migrén

Country Status (35)

Country	Link
US (2)	US20010036943A1 (fr)
EP (1)	EP1272218B1 (fr)
JP (1)	JP2003530345A (fr)
KR (1)	KR20030040201A (fr)
CN (1)	CN1468111A (fr)
AP (1)	AP2002002642A0 (fr)
AR (1)	AR027773A1 (fr)
AT (1)	ATE291438T1 (fr)
AU (1)	AU3768001A (fr)
BG (1)	BG107138A (fr)
BR (1)	BR0109837A (fr)
CA (1)	CA2405142A1 (fr)
CR (1)	CR6767A (fr)
CZ (1)	CZ20023214A3 (fr)
DE (1)	DE60109589T2 (fr)
EA (1)	EA004930B1 (fr)
EE (1)	EE200200579A (fr)
ES (1)	ES2236185T3 (fr)
GT (1)	GT200100055A (fr)
HU (1)	HUP0301822A3 (fr)
IL (1)	IL152076A0 (fr)
IS (1)	IS6560A (fr)
MA (1)	MA26889A1 (fr)
MX (1)	MXPA02009817A (fr)
NO (1)	NO20024734D0 (fr)
OA (1)	OA12241A (fr)
PA (1)	PA8515001A1 (fr)
PE (1)	PE20011307A1 (fr)
PL (1)	PL365957A1 (fr)
SK (1)	SK13952002A3 (fr)
SV (1)	SV2002000377A (fr)
TN (1)	TNSN01053A1 (fr)
WO (1)	WO2001076576A2 (fr)
YU (1)	YU74602A (fr)
ZA (1)	ZA200207996B (fr)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9710536A (pt)	1996-07-24	1999-08-17	Warner Lambert Co	Isobutilgaba e seus derivados para o tratamento da dor
US6464986B1 (en) *	2000-04-14	2002-10-15	Allegan Sales, Inc.	Method for treating pain by peripheral administration of a neurotoxin
US7074961B2 (en)	2000-09-26	2006-07-11	The Brigham And Women's Hospital, Inc.	Antidepressants and their analogues as long-acting local anesthetics and analgesics
WO2002026020A2 (fr) *	2000-09-26	2002-04-04	The Brigham And Women's Hospital, Inc.	Antidepresseurs tricycliques et leurs analogues comme anesthesiques et analgesiques locaux de longue duree
AU2002234836B2 (en) *	2001-04-20	2007-08-23	Pfizer Products Inc.	Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
US8309570B2 (en) *	2001-06-07	2012-11-13	Analgesic Neuropharmaceuticals, Llc	Treatment of central neuropathic pain
AR036040A1 (es)	2001-06-12	2004-08-04	Upjohn Co	Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
SE521512C2 (sv)	2001-06-25	2003-11-11	Niconovum Ab	Anordning för administrering av en substans till främre delen av en individs munhåla
US20040138239A1 (en) *	2001-08-23	2004-07-15	Bruce Frome	Compositions and methods for targeting cerebral circulation and treatment of headache
JP2005504058A (ja)	2001-08-24	2005-02-10	ファルマシアアンドアップジョンカンパニーリミティドライアビリティーカンパニー	疾患の治療のための置換ヘテロアリール−７−アザ［２．２．１］ビシクロヘプタン
CZ2004408A3 (cs)	2001-10-02	2005-03-16	Pharmacia & Upjohn Company	Azabicyklicky substituované kondenzované heteroarylsloučeniny
TWI312285B (en)	2001-10-25	2009-07-21	Depomed Inc	Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en)	2001-10-25	2009-11-03	Depomed, Inc.	Methods of treatment using a gastric retained gabapentin dosage
US6849620B2 (en)	2001-10-26	2005-02-01	Pfizer Inc	N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US6602911B2 (en)	2001-11-05	2003-08-05	Cypress Bioscience, Inc.	Methods of treating fibromyalgia
JP2005510523A (ja)	2001-11-09	2005-04-21	ファルマシアアンドアップジョンカンパニーリミティドライアビリティーカンパニー	アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
WO2003049753A1 (fr) *	2001-12-13	2003-06-19	Council Of Scientific And Industrial Research	Le zingiber officinale de linn et ses extraits et fractions en tant que renforçateurs de biodisponibilite
CN1627944A (zh) *	2002-01-17	2005-06-15	神经能质公司	取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂
WO2003066040A1 (fr) *	2002-02-05	2003-08-14	Ajinomoto Co.,Inc.	Compositions medicinales contenant une gabapentine ou une pregabaline et antagoniste a canal de calcium de type n
EP1482921A1 (fr) *	2002-02-12	2004-12-08	Cypress Bioscience, Inc.	Methodes de traitement du trouble d'hyperactivite avec deficit de l'attention (thada)
WO2003070728A2 (fr)	2002-02-15	2003-08-28	Pharmacia & Upjohn Company	Composes aryle substitues permettant de traiter une maladie
AU2003217275A1 (en)	2002-02-19	2003-09-09	Pharmacia And Upjohn Company	Azabicyclic compounds for the treatment of disease
AU2003219690A1 (en)	2002-02-19	2003-09-09	Pharmacia And Upjohn Company	Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
MXPA04011529A (es) *	2002-04-24	2005-08-15	Cypress Bioscience Inc	Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
US6921538B2 (en) *	2002-05-10	2005-07-26	Allergan, Inc.	Therapeutic treatments for neuropsychiatric disorders
WO2003097038A1 (fr) *	2002-05-14	2003-11-27	Ralph Ryback	Procede de traitement de dermatoses et de dommages tissulaires
JP2006504634A (ja) *	2002-05-15	2006-02-09	アボット・ラボラトリーズ	神経障害性疼痛の治療
MXPA04011416A (es)	2002-05-17	2005-09-30	Othera Pharmaceuticals Inc	Mejora del desarrollo de las cataratas y otras enfermedades oftalmicas.
JP2006509735A (ja) *	2002-10-17	2006-03-23	ノバルティスアクチエンゲゼルシャフト	オクスカルバゼピンまたはその誘導体およびｃｏｘ２インヒビターからなる疼痛処置用医薬組成物
JP4565087B2 (ja)	2002-12-02	2010-10-20	ゼノムリミティッド	新規なχ−コノトキシン・ペプチド（−Ｉ）
EP1578787B1 (fr)	2002-12-02	2012-11-14	Xenome Ltd	Nouveaux peptides de chi-conotoxine (-ii)
US20040204411A1 (en) *	2002-12-17	2004-10-14	Pharmacia Corporation	Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
JP4708795B2 (ja)	2002-12-20	2011-06-22	ニコノヴァムエービー	物理的および化学的に安定なニコチン−含有粒状物質
WO2004078201A1 (fr) *	2003-03-06	2004-09-16	Botulinum Toxin Research Associates, Inc.	Traitement des cephalees et des douleurs faciales chroniques associees a la sinusite au moyen de toxine botulinique
US20040202717A1 (en)	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
WO2004092122A2 (fr) *	2003-04-08	2004-10-28	Algorx Pharmaceuticals, Inc.	Preparation et purification de capsicine synthetique
WO2004105690A2 (fr) *	2003-05-23	2004-12-09	Cypress Bioscience, Inc.	Traitement de douleurs chroniques au moyen de chimiotherapie ou de radiotherapie
US8030300B2 (en)	2003-06-10	2011-10-04	Georgetown University	Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US20050004219A1 (en) *	2003-07-01	2005-01-06	Medtronic, Inc.	Pump systems including injectable gabapentin compositions
US20050004221A1 (en) *	2003-07-01	2005-01-06	Medtronic, Inc.	Intrathecal gabapentin compositions
US20050043407A1 (en) *	2003-08-22	2005-02-24	Pfizer Inc	Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) *	2003-08-22	2005-02-24	Pfizer Inc	Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050058696A1 (en) *	2003-09-12	2005-03-17	Allergan, Inc.	Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7268109B2 (en) *	2003-10-02	2007-09-11	Elan Pharmaceuticals, Inc.	Method for reducing pain
US20050090549A1 (en) *	2003-10-23	2005-04-28	Medtronic, Inc.	Intrathecal gabapentin for treatment of pain
US20050090548A1 (en) *	2003-10-23	2005-04-28	Medtronic, Inc.	Intrathecal gabapentin for treatment of epilepsy
JP2007511520A (ja)	2003-11-13	2007-05-10	ザジェネラルホスピタルコーポレーション	疼痛を治療するための方法
US8871224B2 (en)	2003-12-09	2014-10-28	Allergan, Inc.	Botulinum toxin therapy for skin disorders
HU230403B1 (hu) *	2003-12-19	2016-04-28	Pál Kocsis	Nátrium csatorna blokkoló és szerotonin újrafelvétel gátló tartalmú gyógyszerkészítmény
US20100266638A1 (en) *	2004-02-26	2010-10-21	Allergan, Inc.	Headache treatment method
US20050220734A1 (en) *	2004-04-02	2005-10-06	Allergan, Inc.	Therapy for melanin related afflictions
EP1765300A2 (fr) *	2004-06-10	2007-03-28	Duramed Pharmaceuticals, Inc.	Formulations de sumatriptan absorbables au travers des membranes biologiques, et methodes de production et d'utilisation desdites formulations
MY147767A (en)	2004-06-16	2013-01-31	Janssen Pharmaceutica Nv	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2006047279A2 (fr) *	2004-10-21	2006-05-04	University Of Iowa Research Foundation	Systeme d'administration in situ de medicaments a liberation controlee
WO2006053012A2 (fr) *	2004-11-10	2006-05-18	Trinity Laboratories, Inc.	Nouvelles compositions pharmaceutiques destinees a traiter la douleur chronique acquise et la dysphorie associee
EA200701131A1 (ru) *	2004-11-24	2007-12-28	Алгоркс Фармасьютикалз, Инк.	Гелеобразная препаративная форма капсаициноида и способы её применения
US20060252745A1 (en)	2005-05-06	2006-11-09	Almeida Jose L D	Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
AU2006249577A1 (en)	2005-05-20	2006-11-30	Janssen Pharmaceutica N.V.	Process for preparation of sulfamide derivatives
US7994220B2 (en)	2005-09-28	2011-08-09	Cypress Bioscience, Inc.	Milnacipran for the long-term treatment of fibromyalgia syndrome
US8716231B2 (en)	2005-12-19	2014-05-06	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en)	2005-12-19	2014-04-08	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en)	2005-12-19	2015-01-20	Janssen Pharmaceutica Nv	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8492431B2 (en)	2005-12-19	2013-07-23	Janssen Pharmaceutica, N.V.	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en)	2005-12-19	2013-07-30	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20090176882A1 (en) *	2008-12-09	2009-07-09	Depomed, Inc.	Gastric retentive gabapentin dosage forms and methods for using same
GB0603008D0 (en) *	2006-02-14	2006-03-29	Portela & Ca Sa	Method
WO2007104573A2 (fr)	2006-03-16	2007-09-20	Niconovum Ab	Composition améliorée de tabac à priser
JP2007308403A (ja) *	2006-05-17	2007-11-29	Kenji Yoshida	皮膚外用剤
WO2007137167A2 (fr)	2006-05-19	2007-11-29	Janssen Pharmaceutica N.V.	Thérapie combinée pour le traitement de l'épilepsie et de troubles apparentés
CN101074935B (zh) *	2006-05-19	2011-03-23	清华大学	探测器阵列及设备
FR2902341B1 (fr)	2006-06-16	2011-02-25	Scras	Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
WO2008010223A2 (fr) *	2006-07-17	2008-01-24	Ramot At Tel Aviv University Ltd.	Conjugués de gaba anti-douleur
WO2008020651A1 (fr) *	2006-08-17	2008-02-21	Kyushu University, National University Corporation	antagoniste de récepteur P2X4
SA07280459B1 (ar)	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US7645767B2 (en) *	2006-08-31	2010-01-12	Trinity Laboratories, Inc.	Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
US20080119820A1 (en)	2006-09-20	2008-05-22	Phan Phillip C	Methods for Delivering Volatile Anesthetics for Regional Anesthesia and/or Pain Relief
US20100048605A1 (en) *	2006-12-11	2010-02-25	University Of Kentucky Research Foundation	Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
FR2910327B1 (fr)	2006-12-22	2013-04-26	Scras	Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
GB0700773D0 (en)	2007-01-15	2007-02-21	Portela & Ca Sa	Drug therapies
MX2010002692A (es)	2007-09-13	2010-06-01	Concert Pharmaceuticals Inc	Sintesis de catecoles deuterados y derivados de benzo[d][1,3]dioxoles de los mismos.
US20100312073A1 (en) *	2008-01-31	2010-12-09	David Yarnitsky	Method of predicting pain medication efficacy
FR2930447B1 (fr)	2008-04-25	2010-07-30	Sod Conseils Rech Applic	Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
ES2563061T3 (es)	2008-04-28	2016-03-10	Zogenix, Inc.	Nuevas formulaciones para el tratamiento de la migraña
EA018567B1 (ru)	2008-06-23	2013-08-30	Янссен Фармацевтика Нв	Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en)	2008-07-22	2014-08-26	Janssen Pharmaceutica Nv	Substituted sulfamide derivatives
US20100184685A1 (en) *	2009-01-19	2010-07-22	Zavala Jr Gerardo	Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
PT2582366E (pt)	2010-06-15	2016-01-26	Gruenenthal Gmbh	Combinação terapêutica para o tratamento da dor
US8916610B2 (en)	2010-09-22	2014-12-23	Ramot At Tel-Aviv University Ltd.	Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
AP3815A (en)	2010-12-22	2016-09-30	Purdue Pharma Lp	Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en)	2010-12-23	2022-10-24	Purdue Pharma Lp	Tamper resistant solid oral dosage forms
CN103764136A (zh) *	2011-02-18	2014-04-30	雀巢产品技术援助有限公司	用于治疗、减轻或预防动物神经系统损害的方法和组合物
ES2387973B1 (es) *	2011-03-18	2013-10-01	Dr Healthcare España, S. L.	Composiciones tópicas que contienen diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que comportan un aumento del dolor.
WO2013023155A1 (fr)	2011-08-11	2013-02-14	Xenoport, Inc.	Formes cristallines anhydres et hémihydratées d'un promédicament (r)-baclofène, procédés de synthèse et procédés d'utilisation
KR20150042269A (ko) *	2012-08-16	2015-04-20	얀센 파마슈티카 엔.브이.	N형 칼슘 채널 차단제로서의 치환된 피라졸
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US10751287B2 (en)	2013-03-15	2020-08-25	Purdue Pharma L.P.	Tamper resistant pharmaceutical formulations
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
CA3042642A1 (fr)	2013-08-12	2015-02-19	Pharmaceutical Manufacturing Research Services, Inc.	Comprime extrude anti-abus a liberation immediate
US9453002B2 (en)	2013-08-16	2016-09-27	Janssen Pharmaceutica Nv	Substituted imidazoles as N-type calcium channel blockers
US9492444B2 (en)	2013-12-17	2016-11-15	Pharmaceutical Manufacturing Research Services, Inc.	Extruded extended release abuse deterrent pill
WO2015095391A1 (fr)	2013-12-17	2015-06-25	Pharmaceutical Manufacturing Research Services, Inc.	Comprimé extrudé anti-abus à libération prolongée
CA2955229C (fr)	2014-07-17	2020-03-10	Pharmaceutical Manufacturing Research Services, Inc.	Forme posologique remplie de liquide anti-abus a liberation immediate
EP3209282A4 (fr)	2014-10-20	2018-05-23	Pharmaceutical Manufacturing Research Services, Inc.	Forme galénique anti-abus de remplissage de liquide à libération prolongée
CN104758933A (zh) *	2014-10-29	2015-07-08	吴鑫欣	治疗神经卡压、神经瘤疼痛的药物和给药系统
WO2018175696A1 (fr) *	2017-03-22	2018-09-27	Bonti, Inc.	Neurotoxines de botulinum pour le traitement de lésions traumatiques
WO2018183320A1 (fr) *	2017-03-31	2018-10-04	Depco, Inc.	Mastic thérapeutique à analgésiques et/ou révulsifs
WO2018191480A1 (fr) *	2017-04-12	2018-10-18	Synergistic Therapeutics. Llc	Lotion thérapeutique contre la douleur neuropathique
KR101944113B1 (ko)	2017-09-28	2019-01-30	동의대학교 산학협력단	급성 안면통증 예방 및 개선용 조성물
KR102156627B1 (ko)	2018-12-20	2020-09-16	동의대학교 산학협력단	보스웰리아 추출물 및 산자나무 추출물을 포함하는 급성 안면통증 예방 및 개선용 조성물
KR102156438B1 (ko)	2018-12-20	2020-09-16	동의대학교 산학협력단	급성 안면통증 예방 및 개선용 조성물
CN115054601B (zh) *	2022-03-21	2024-04-26	中山大学附属第三医院	一种可注射的缓释镇痛复合物及其制备方法、应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3621707B2 (ja) *	1996-10-30	2005-02-16	ファイザー・インク	ピリドン―縮合したアザ二環式―またはシチシン誘導体、その製法および嗜癖治療におけるその用途
EP0955301A3 (fr) *	1998-04-27	2001-04-18	Pfizer Products Inc.	Dérivés de 7-aza-bicyclo[2.2.1]-heptane, leur préparation et utilisation sur la base d'affinité pour les recepteurs de l'acetylcholine nicotinique neuronaux
KR100420423B1 (ko) *	1998-04-29	2004-03-04	화이자 프로덕츠 인코포레이티드	아릴 축합된 아자 다환식 화합물
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

2000
- 2000-12-18 US US09/740,307 patent/US20010036943A1/en not_active Abandoned
2001
- 2001-03-16 EE EEP200200579A patent/EE200200579A/xx unknown
- 2001-03-16 ES ES01910097T patent/ES2236185T3/es not_active Expired - Lifetime
- 2001-03-16 YU YU74602A patent/YU74602A/sh unknown
- 2001-03-16 IL IL15207601A patent/IL152076A0/xx unknown
- 2001-03-16 EP EP01910097A patent/EP1272218B1/fr not_active Expired - Lifetime
- 2001-03-16 CN CNA01816840XA patent/CN1468111A/zh active Pending
- 2001-03-16 EA EA200200910A patent/EA004930B1/ru not_active IP Right Cessation
- 2001-03-16 KR KR1020027013380A patent/KR20030040201A/ko not_active Application Discontinuation
- 2001-03-16 BR BR0109837-3A patent/BR0109837A/pt not_active IP Right Cessation
- 2001-03-16 MX MXPA02009817A patent/MXPA02009817A/es unknown
- 2001-03-16 JP JP2001574094A patent/JP2003530345A/ja active Pending
- 2001-03-16 HU HU0301822A patent/HUP0301822A3/hu unknown
- 2001-03-16 DE DE60109589T patent/DE60109589T2/de not_active Expired - Fee Related
- 2001-03-16 AP APAP/P/2002/002642A patent/AP2002002642A0/en unknown
- 2001-03-16 CA CA002405142A patent/CA2405142A1/fr not_active Abandoned
- 2001-03-16 AT AT01910097T patent/ATE291438T1/de not_active IP Right Cessation
- 2001-03-16 CZ CZ20023214A patent/CZ20023214A3/cs unknown
- 2001-03-16 SK SK1395-2002A patent/SK13952002A3/sk not_active Application Discontinuation
- 2001-03-16 WO PCT/IB2001/000391 patent/WO2001076576A2/fr not_active Application Discontinuation
- 2001-03-16 PL PL01365957A patent/PL365957A1/xx not_active Application Discontinuation
- 2001-03-16 OA OA1200200304A patent/OA12241A/en unknown
- 2001-03-16 AU AU37680/01A patent/AU3768001A/en not_active Abandoned
- 2001-04-05 GT GT200100055A patent/GT200100055A/es unknown
- 2001-04-05 PE PE2001000319A patent/PE20011307A1/es not_active Application Discontinuation
- 2001-04-05 AR ARP010101625A patent/AR027773A1/es not_active Application Discontinuation
- 2001-04-06 TN TNTNSN01053A patent/TNSN01053A1/fr unknown
- 2001-04-06 SV SV2001000377A patent/SV2002000377A/es not_active Application Discontinuation
- 2001-04-09 PA PA20018515001A patent/PA8515001A1/es unknown
2002
- 2002-09-20 IS IS6560A patent/IS6560A/is unknown
- 2002-09-23 BG BG107138A patent/BG107138A/xx unknown
- 2002-10-02 CR CR6767A patent/CR6767A/es unknown
- 2002-10-02 MA MA26846A patent/MA26889A1/fr unknown
- 2002-10-02 NO NO20024734A patent/NO20024734D0/no not_active Application Discontinuation
- 2002-10-04 ZA ZA200207996A patent/ZA200207996B/en unknown
2003
- 2003-01-21 US US10/348,381 patent/US20030133951A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2001076576A2 (fr)	2001-10-18
DE60109589T2 (de)	2005-09-01
EA200200910A1 (ru)	2003-02-27
IL152076A0 (en)	2003-05-29
PL365957A1 (en)	2005-01-24
YU74602A (sh)	2006-05-25
IS6560A (is)	2002-09-20
CA2405142A1 (fr)	2001-10-18
GT200100055A (es)	2001-12-31
WO2001076576A3 (fr)	2002-06-20
EE200200579A (et)	2004-06-15
EP1272218A2 (fr)	2003-01-08
ATE291438T1 (de)	2005-04-15
CR6767A (es)	2004-06-09
DE60109589D1 (de)	2005-04-28
PA8515001A1 (es)	2002-02-21
JP2003530345A (ja)	2003-10-14
ZA200207996B (en)	2003-10-20
AU3768001A (en)	2001-10-23
HUP0301822A3 (en)	2005-06-28
MA26889A1 (fr)	2004-12-20
NO20024734D0 (no)	2002-10-02
AP2002002642A0 (en)	2002-12-31
TNSN01053A1 (fr)	2005-11-10
KR20030040201A (ko)	2003-05-22
EA004930B1 (ru)	2004-10-28
CZ20023214A3 (cs)	2003-11-12
CN1468111A (zh)	2004-01-14
US20030133951A1 (en)	2003-07-17
BR0109837A (pt)	2003-01-21
MXPA02009817A (es)	2003-03-27
BG107138A (en)	2003-05-30
OA12241A (en)	2004-01-27
EP1272218B1 (fr)	2005-03-23
US20010036943A1 (en)	2001-11-01
SV2002000377A (es)	2002-07-03
HUP0301822A2 (hu)	2003-11-28
ES2236185T3 (es)	2005-07-16
AR027773A1 (es)	2003-04-09
PE20011307A1 (es)	2001-12-28

Publication	Publication Date	Title
SK13952002A3 (sk)	2003-12-02	Farmaceutická kompozícia na liečenie akútnej, chronickej a/alebo neuropatickej bolesti a migrén
RU2135179C1 (ru)	1999-08-27	Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
JP2000508341A (ja)	2000-07-04	片頭痛の治療法及び薬効の強化組成物
JP2002506047A (ja)	2002-02-26	Ｎｍｄａレセプター拮抗薬及び麻酔性鎮痛薬を含む鎮痛組成物。
JP2014196328A (ja)	2014-10-16	ニコチン性アセチルコリンα７受容体アゴニストの組合せ剤
JP2009531434A (ja)	2009-09-03	痛みの治療
PT1536782E (pt)	2007-06-27	Combinação sinérgica de um ligando alfa-2-delta e um inibidor pdev para ser utilizada no tratamento da dor
US20110034565A1 (en)	2011-02-10	Psycho-pharmaceuticals
CA2369789A1 (fr)	2002-08-02	Traitement combine de la depression
KR20130101524A (ko)	2013-09-13	5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
US5340826A (en)	1994-08-23	Pharmaceutical agents for treatment of urinary incontinence
WO2002036113A1 (fr)	2002-05-10	Composition comprenant des agonistes (5ht-4) et des antagonistes (5ht-2, 5ht-3) recepteurs de la serotonine
JP2014505113A (ja)	2014-02-27	末梢作用性μオピオイドアンタゴニスト
SK14502000A3 (sk)	2001-05-10	Kombinácie liekov n. a. r. i. (inhibítorov reaktivácie noradrenalínu), výhodne reboxetínu, a pindololu
JP2000501709A (ja)	2000-02-15	疼痛治療用組成物
JP2022542698A (ja)	2022-10-06	セロトニン作動薬及び５－ｈｔ１ａ受容体アンタゴニスト
JP2016029033A (ja)	2016-03-03	組合せ物
WO1999059635A1 (fr)	1999-11-25	Utilisation d'un inhibiteur de cox-2 et d'un antagoniste du recepteur nk-1 dans le traitement de l'inflammation
US20090270400A1 (en)	2009-10-29	Painkilling association comprising a dihydroimidazopyrazine derivative
CN1466587A (zh)	2004-01-07	含有2-芳基-8-氧代二氢嘌呤衍生物作为活性成分的痴呆症治疗剂
JP2006306738A (ja)	2006-11-09	神経因性疼痛治療剤
MXPA98004519A (en)	1999-04-06	Composition to treat do

Legal Events

Date	Code	Title	Description
2010-12-07	FC9A	Refused patent application